Navigating FDA Compliance and Reducing COGS 35% for an Australian Health Brand

Client Profile

An Australian health supplement brand manufacturing a line of premium nutraceuticals — collagen peptides, adaptogenic blends, and targeted vitamin complexes. The active ingredients were sourced from six different Chinese suppliers, blended and packaged in Australia. The brand had strong traction domestically but had been repeatedly blocked from entering the US market due to FDA compliance gaps. Their packaging was non-compliant with 21 CFR 101 labeling requirements, their Chinese ingredient suppliers had never undergone FDA facility registration, and their component traceability systems couldn’t meet US regulatory standards.

The Challenge

Every attempt to enter the US market had ended at the same wall: FDA compliance. Two shipments had been detained at the border. A third was refused entry entirely. The brand had spent $180,000 on regulatory consultants who identified the problems but offered no path to solve them — especially not for Chinese-sourced components, where supplier cooperation was essential but absent.

Meanwhile, the brand’s COGS was unsustainably high at $22.40 per unit. The six Chinese ingredient suppliers were small, fragmented, and each was charging premium prices for small-volume orders. The founder faced a painful choice: raise prices and lose domestic competitiveness, or abandon the US market opportunity entirely.

“We built a product Australians loved, but the US market was a locked door — and six different suppliers each held a different key.”

Our Solution

LeelineGroup took a dual-track approach: compliance and cost, solved simultaneously by restructuring the supplier base.

On the compliance track, we identified two FDA-registered ingredient manufacturers in our network — both with existing US market experience and compliant documentation packages. We helped the client complete FDA facility registration, prepared 510(k) submissions for applicable products, and overhauled all labeling to meet 21 CFR 101 requirements (nutrition facts panels, supplement facts formatting, allergen declarations, and ingredient naming conventions).

On the cost track, consolidating from six small suppliers to two larger, FDA-registered manufacturers unlocked significant volume pricing. Both new suppliers were equipped for batch-level traceability — raw material lot numbers tracked from receipt through production to finished goods, satisfying FDA’s 21 CFR Part 111 GMP requirements for dietary supplements.

The entire transition — supplier audit, compliance documentation, packaging redesign, test batch production, and first commercial shipment — was completed in seven months.

Dual-Track Transformation:

• Compliance: FDA facility registration, 510(k) submissions, 21 CFR 101 labeling overhaul
• Supply Base: 6 fragmented suppliers → 2 FDA-registered partners
• Traceability: Lot-level tracking from raw material to finished good
• Cost: Volume consolidation unlocked 35% per-unit COGS reduction

Results

Technical Results

Metric	Before	After
FDA Registration Status	Not registered — at risk of detention	Full FDA facility registration + 510(k)
Labeling Compliance	Non-compliant — missing 7 required fields	21 CFR 101 compliant across all SKUs
Component Traceability	No batch-level tracking	Full lot-level traceability

Commercial Results

Metric	Before	After
Per-Unit COGS	$22.40	$14.56
Annual Procurement Spend	$1.12M across 6 suppliers	$730K across 2 suppliers
Market Access	Australia only (3M TAM)	Australia + US (350M TAM)

Within seven months, the brand achieved full FDA compliance, reduced per-unit COGS by 35%, and successfully entered the US market. The first US shipment cleared customs without a single hold. The combination of lower costs and expanded market access transformed the business — US sales accounted for 40% of revenue within the first year. The brand is now exploring EU market entry using the same compliant supply base.

---

Regulatory hurdles blocking your market expansion? We solve compliance and cost in one move.